L-Tryptophan
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | L-Tryptophan |
|---|---|
| Chemical class | Essential aromatic α-amino acid — indole side chain |
| CAS | 73-22-3 (L-tryptophan) · 54-12-6 (DL-tryptophan) |
| Molecular weight | 204.23 g/mol — the largest proteinogenic amino acid |
| Metabolic split | ~95% kynurenine pathway to NAD⁺ · ~1–2% to serotonin |
| Niacin equivalence | 60 mg tryptophan ≈ 1 mg niacin equivalent |
| Claim strength | High for the NAD⁺ conversion and transport competition; Emerging for sleep |
| Buy from Herbuno | L-Tryptophan 99% Powder · DL-Tryptophan 99% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: From the Greek tryptos, pounded, plus phainein, to appear — Frederick Hopkins and Sydney Cole isolated it in 1901 from casein using trypsin digestion, and the name records the method. It is the largest of the proteinogenic amino acids and the least abundant in most proteins, which is the reason it is limiting in several plant protein sources.
Metabolic position: Tryptophan's reputation rests almost entirely on a minority pathway. The overwhelming majority of tryptophan catabolism — around 95% — proceeds down the kynurenine pathway, initiated by tryptophan 2,3-dioxygenase in liver and indoleamine 2,3-dioxygenase elsewhere, through kynurenine and quinolinic acid to NAD⁺. Only approximately 1 to 2% is hydroxylated by tryptophan hydroxylase to 5-hydroxytryptophan and decarboxylated to serotonin, and from there to melatonin in the pineal gland.
The 1989 EMS outbreak: Tryptophan carries the most consequential manufacturing-quality history of any amino acid. In 1989 an outbreak of eosinophilia-myalgia syndrome affected over 1,500 people in the United States with several dozen deaths, and epidemiological investigation traced the cases to L-tryptophan from a single manufacturer following a change in its fermentation and purification process. Candidate contaminants were identified, including the dimer 1,1'-ethylidenebis-L-tryptophan. Regulatory withdrawal of tryptophan supplements followed and persisted for years. Causality was never definitively settled, but the manufacturing association was strong and the episode permanently changed specification expectations for this material.
Commercial source: L-tryptophan is produced by fermentation using engineered Escherichia coli or Corynebacterium glutamicum, and also by enzymatic conversion from indole and serine or from indole-3-pyruvate. Large volumes go to animal feed, where tryptophan is a limiting amino acid in some diets. The specification gap between feed and supplement grade matters more here than almost anywhere, for the reason above.
Evidence for L-Tryptophan Applications
The EMS history should be the first item on any tryptophan specification discussion. The 1989 outbreak, affecting over 1,500 people with several dozen deaths, was traced epidemiologically to material from one manufacturer after a documented process change, with the tryptophan dimer 1,1'-ethylidenebis-L-tryptophan among the identified candidate contaminants. Causality remains formally unsettled, but the practical lesson is unambiguous: tryptophan is a material where process-related impurity control, not assay, is the quality question. A certificate showing 99% assay and nothing else is not an adequate specification for this amino acid. Claim strength: High.
Roughly 95% of tryptophan goes to NAD⁺, not to serotonin, and this proportion reframes most tryptophan claims. The kynurenine pathway dominates catabolism, which is why tryptophan contributes meaningfully to niacin status — the accepted conversion is approximately 60 milligrams of tryptophan to 1 milligram of niacin equivalent, and this is the biochemistry behind pellagra appearing on maize-based diets, maize protein being low in tryptophan. A tryptophan dose is substantially a niacin precursor dose, which is rarely how it is positioned. Claim strength: High.
Large neutral amino acid transport competition is the single most actionable formulation fact about tryptophan. Tryptophan competes with the branched-chain amino acids, tyrosine and phenylalanine for the same L-type transporter at the blood-brain barrier, and because tryptophan is the least abundant of the group, it loses that competition easily. Consequently a tryptophan dose taken with protein, or alongside branched-chain amino acids, delivers much less to the brain than the same dose taken alone. Conversely carbohydrate raises insulin, which lowers plasma branched-chains and improves tryptophan's ratio. A formulation ignoring this is working against itself. Claim strength: High.
The sleep evidence is modest and dated rather than absent. Controlled trials from the 1970s and 1980s examined L-tryptophan at around 1 gram and upward for sleep onset latency, with several reporting reductions, and the mechanism through serotonin and melatonin is coherent. The trials are old, small by current standards, and the regulatory withdrawal after 1989 interrupted the research programme. Contemporary replication is limited. This is a real but thin literature, and sleep claims are regulated in most markets regardless. Claim strength: Emerging.
Serotonin syndrome is a genuine interaction risk and warrants explicit labelling rather than silence. Tryptophan supplies substrate to serotonin synthesis, so combining it with selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, triptans, tramadol or other serotonergic agents carries a theoretical and in some reports realised risk of excess serotonergic activity. The same caution applies to 5-hydroxytryptophan, which bypasses the rate-limiting hydroxylation and is accordingly more potent per milligram. A tryptophan product should carry an interaction statement. Claim strength: Moderate.
Tryptophan is limiting in several plant proteins, which gives it a legitimate fortification application. Maize protein is notably tryptophan-poor, and several other cereal and legume isolates are relatively low in it, so tryptophan addition raises the amino acid score where tryptophan rather than lysine or methionine is the first limiting residue. Because tryptophan is the least abundant amino acid in most proteins, the inclusion required is small in absolute terms. This is routine protein formulation and the strongest non-claim application. Claim strength: High.
Sourcing L-tryptophan from Herbuno. We supply L-tryptophan and DL-tryptophan at 99%.
Specify process-related impurities, not just assay. The 1989 EMS outbreak was traced to material from one manufacturer after a process change, and tryptophan dimers and related condensation products are the relevant class — a 99% assay certificate alone does not address them. Require the production route, the organism and substrate, and an impurity profile by HPLC with a stated dimer limit. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
L-tryptophan is dosed as the free amino acid at 99%, with no salt conversion. Adult requirement is around 4 milligrams per kilogram daily, the lowest of the essential amino acids, reflecting its low abundance in protein. Doses in the older sleep literature ran from around 1 gram upward. For protein fortification the inclusion is calculated against the base protein's measured profile and is small in absolute terms, typically well under 1% of protein weight even for a maize base. Niacin-equivalent contribution can be calculated at 60 milligrams tryptophan per milligram of niacin equivalent.
Impurity specification is where this material differs from every other amino acid in the catalogue. Require an HPLC impurity profile with a stated limit for tryptophan dimers and condensation products, the production route named, the fermentation organism and substrate stated, and confirmation that the process has not changed since qualification. The 1989 episode turned on exactly that last point: the implicated material came from a manufacturer that had altered its fermentation strain and reduced a purification step. Process-change notification should be a contractual term rather than a courtesy.
Formulate around the transport competition or the dose is wasted. Tryptophan competes with branched-chains, tyrosine and phenylalanine for the blood-brain barrier L-transporter and, being least abundant, loses. A tryptophan product intended for any central effect should be dosed away from protein meals and should not be co-formulated with branched-chain amino acids, which is a combination that appears surprisingly often. Carbohydrate co-ingestion improves the ratio by lowering plasma branched-chains via insulin, so a small carbohydrate component is a rational design choice rather than a filler.
Handling is manageable with one real constraint. L-tryptophan is poorly soluble in water, at around 1.1 grams per 100 millilitres at room temperature, which limits liquid applications significantly. It is stable to heat and across a broad pH range but is light-sensitive — the indole ring is susceptible to photo-oxidation — so opaque or amber packaging and protection during processing are advisable. Taste is bitter. It participates in Maillard reactions and the indole ring can generate off-notes in thermally processed products.
For analytical control, specify identity and assay by HPLC with optical rotation confirming L-configuration and stating whether L- or DL- is required, since the racemate is a separate article and a standard assay will not distinguish them. Beyond that, specify the dimer and related-substance profile as above, heavy metals, residual solvents, microbiological limits, loss on drying and sulphated ash, plus residual host-cell protein and endotoxin for fermentation-derived material. Given the feed-grade volume in this market, state the grade explicitly rather than relying on a general amino acid specification.
Two label items should be settled at formulation stage rather than at registration. First, an interaction statement covering serotonergic medication — SSRIs, MAOIs, triptans, tramadol — since tryptophan supplies serotonin substrate and the theoretical serotonin syndrome risk is one regulators and pharmacists both look for. Second, the regulatory status of tryptophan itself, which varies by market and still carries residual restrictions in some jurisdictions as a legacy of the 1989 withdrawal; the position differs by country and by product category and should be confirmed per target market. Neither is addressed by reformulation, so both belong at the front of the development process.
Frequently Asked Questions — L-Tryptophan
What happened in 1989 and does it still matter?
An outbreak of eosinophilia-myalgia syndrome affected over 1,500 people in the US with several dozen deaths, traced epidemiologically to L-tryptophan from one manufacturer after a fermentation and purification process change; tryptophan dimers were among the candidate contaminants. Causality was never formally settled, but it permanently changed what an adequate tryptophan specification looks like.
So what should I specify?
Process-related impurities, not just assay. Require an HPLC impurity profile with a stated dimer and related-substance limit, the production route, the organism and substrate, and contractual process-change notification. A 99% assay certificate alone does not address the question this material raises.
Does tryptophan mainly make serotonin?
No — about 95% goes down the kynurenine pathway to NAD+, and only around 1 to 2% to serotonin. That makes a tryptophan dose substantially a niacin precursor dose: roughly 60 mg tryptophan per 1 mg niacin equivalent. It is the biochemistry behind pellagra on maize-based diets, maize protein being tryptophan-poor.
Why would my tryptophan product not work?
Transport competition, most likely. Tryptophan competes with branched-chains, tyrosine and phenylalanine for the blood-brain barrier L-transporter, and being the least abundant it loses. Dosed with protein or alongside BCAAs, very little reaches the brain. Carbohydrate helps, by lowering plasma branched-chains via insulin.
What interaction statement does it need?
Serotonergic medication — SSRIs, MAOIs, triptans, tramadol. Tryptophan supplies serotonin substrate, and the theoretical serotonin syndrome risk is something regulators and pharmacists both look for. The same applies more strongly to 5-HTP, which bypasses the rate-limiting hydroxylation and is more potent per milligram.
Any formulation constraints?
Two. Poor solubility, about 1.1 g per 100 ml, which limits liquids substantially. And light sensitivity — the indole ring photo-oxidises, so use opaque or amber packaging and protect during processing. Also confirm tryptophan's regulatory status per market; residual restrictions persist in some jurisdictions from the 1989 withdrawal.